Squarepoint
VIR icon

Squarepoint’s Vir Biotechnology VIR Stock Holding History

Squarepoint’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-52,500
Closed -$385K – 5476
2024
Q4 		$385K Hold
52,500
– – ﹤0.01% 3957
2024
Q3 		$393K Sell
52,500
-49,400
-48% -$429K ﹤0.01% 3277
2024
Q2 		$907K Buy
+101,900
New +$977K ﹤0.01% 2633

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Squarepoint's VIR Position: Q1 2026 in Review

Squarepoint increased its Vir Biotechnology (VIR) stake by 25% in Q1 2026, buying an estimated $41K and bringing the position to 26,013 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #3875.

Squarepoint first reported a position in VIR in Q4 2019 and has held it in 15 quarters since. The position peaked at $3.07M in Q1 2022. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Squarepoint held 26,013 shares of Vir Biotechnology worth $233K as of Q1 2026.
  • Squarepoint bought 5,146 Vir Biotechnology shares in Q1 2026, an estimated $41K.
  • Vir Biotechnology made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3875 holding.
  • Squarepoint first reported a position in Vir Biotechnology in Q4 2019 and has held it in 15 quarters since.
  • Squarepoint's Vir Biotechnology position peaked at $3.07M in Q1 2022.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.